USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
18 Jan 2022 | 03:45 PM GMT

Standalone DTx: clinical and economic evidence

Anchored by:

Owen McCarthy
President, Co-Founder
MEDRHYTHMS
Eugene Borukhovich
Co-Founder & COO
YOURCOACH HEALTH

Participants:

Eugene Borukhovich Co-Founder & COOYourCoach Health
Eugene Borukhovich
Co-Founder & COOYourCoach Health
Owen McCarthy President, Co-FounderMedRhythms
Owen McCarthy
President, Co-FounderMedRhythms
Alex Morozov SVP Head of Clinical DevelopmentExelixis
Alex Morozov
SVP Head of Clinical DevelopmentExelixis
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Gabriele Tundo PartnerPlexus Ventures
Gabriele Tundo
PartnerPlexus Ventures
Lindsay Ayearst Chief Scientific OfficerRevibe Technologies
Lindsay Ayearst
Chief Scientific OfficerRevibe Technologies
Matthias Zenker Chief Medical Solutions OfficerGAIA American Inc.
Matthias Zenker
Chief Medical Solutions OfficerGAIA American Inc.
Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Paul Upham Global Head of Smart DevicesRoche / Genentech
Paul Upham
Global Head of Smart DevicesRoche / Genentech
Ravi Janapureddy Co-founder & CEOResony
Ravi Janapureddy
Co-founder & CEOResony
Steven Paalz Web DeveloperNight Market
Steven Paalz
Web DeveloperNight Market
Vasyl Pyrozhyk Vice PresidentSMBC
Vasyl Pyrozhyk
Vice PresidentSMBC
Vasyl Pyrozhyk Vice President - HealthcareSumitomo Mitsui Banking Corporation
Vasyl Pyrozhyk
Vice President - HealthcareSumitomo Mitsui Banking Corporation

About this Meeting

As DTx companies look for their place in the market, in order to convince the different healthcare stakeholders (payers, physicians, etc), they need to generate clinical and economic data that validates their products and services. The evidence requirements and challenges to generate it differ depending on the type of DTx; on this occasion we will focus on standalone DTx (DTx products used independently of drugs). Join this informal conversation with other senior leaders in the space to discuss the following: 

  •  Level of clinical and economic evidence required for standalone DTx - how does this change depending on the stakeholder, mode of action, risk of the product, disease, etc?  
  •  Particularities and Challenges of the Study Design for standalone DTx (e.g selecting the right comparators, inclusion/exclusion criteria, endpoints, the role of RWE, etc)  
  •  What is the most efficient way to generate economic evidence? What methods can be used to generate this data in the different stages of a product?